CNSI Cambridge Neuroscience Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CNSI Cambridge Neuroscience

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: TheSlowLane who wrote (86)	2/10/1997 9:13:00 AM
From: TheSlowLane	of 675

The BG author comments: The question was: Why was Cerestat not mentioned in the article? Atex TO: MAIL HUB:SMTP%"pferguson@exapps.com";Cerestat FROM: KNOX 10-FEB-97,08:59 Short answer to your question is time, space and stage of development. As you may know, there are a number of neuroprotectants in various stages of development. Given space limitations, I couldn't mention them all. Citicoline and lubeluzole, I am told by a number of stroke researchers, currently seem to be furthest along in terms of Phase III data. There was a Phase I study of Cerestat (aptiganel HC1) presented last Thursday in Anaheim, and also a Phase III update of Cerestat that day. Unfortunately, I did not know the results of those trials when I wrote today's article. (I did not go to Anaheim.) Cerestat was not represented among the clinical trials presented Saturday morning. I will be interested in following the progress of Cerestat as well as the others. Thanx for your interest. RAK

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next